37 Cognitive Impact of SRS vs. WBRT: Systematic Review & Meta-analysis Table 3: Study characteristics and baseline patient characteristics categorized by type of radiotherapy (continued) RT type Authors and year of publication Study type Radiation schedule N Sex (M:F) Median age in years (range or N of patients) KPS (N of patients) Number of BMs (N of patients) Median total volume of BMs in cc Median overall survival in months Primary tumor location (N of patients) SRS SRS 25 Gy/1 fr or 28-35 Gy/4 fr 7 2:5 56.3 (N.A.) 70 (1) 80 (1) 90 (5) 1 (7) 2.8 N.A. Lung (6) Breast (0) Other (1) Chang et al., 2007 29 Prospective pilot study SRS median 20 Gy (14-21 Gy) 15 5:10 64.9 (31.5-77) 70 (1) 80 (2) 90 (8) 100 (4) 1 (11) 2-3 (4) 1.8 7.2 Lung (8) Renal (3) Melanoma (4) Chang et al., 2009 31 RCT SRS median 19 Gy (15-20 Gy) 30 12:18 63 (35-82) ≥80 (30) 1 (18) 2-3 (12) 1.4 15.2 Lung (16) Breast (4) Renal (2) Melanoma (4) Other (4) Brown et al., 2016 32 RCT SRS median 20 Gy (14-21 Gy) 111 54:57 <60 (53) ≥60 (58) N.A. 1 (55) 2 (39) 3 (17) N.A. 10.4 Lung (80) Breast (11) Melanoma (3) Other (17) Habets et al., 2016 30,43 Prospective trial SRS median 19 Gy (15-20 Gy) 97 46:51 63 (33-82) 60-80 (62) ≥90 (35) 1 (43) 2 (31) 3 (18) 4 (5) 7.8 7.7 Lung (48) Breast (8) Melanoma (9) Other (32) Minniti et al., 2020 44 Prospective trial SRS 22 Gy (<2cm lesion) 16-18 Gy (≥2cm lesion) 40 23:17 57 (37-74) ≥60 (40) 10-14 (32) 15-21 (8) 4.7 14.1 Lung (17) Breast (7) Melanoma (10) Kidney (6) Abbreviations: BMs, brain metastases; Fr, fractions; Gy, RT dose in Gray; HA-WBRT, hippocampal avoidance whole-brain radiotherapy; KPS, Karnofsky Performance Status; N, number of patients; N.A., not available; RCT, randomized controlled trial; RT, radiotherapy; SIB, simultaneous integrated boost; SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy; N.A. not available 2
RkJQdWJsaXNoZXIy MTk4NDMw